News articles about Enanta Pharmaceuticals (NASDAQ:ENTA) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.2521289174732 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
A number of analysts have recently commented on ENTA shares. TheStreet upgraded Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday, December 13th. Royal Bank of Canada restated a “buy” rating and issued a $54.00 target price on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. JPMorgan Chase & Co. cut Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $51.25.
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded up $3.32 during trading on Monday, hitting $76.74. The company’s stock had a trading volume of 365,989 shares, compared to its average volume of 230,467. Enanta Pharmaceuticals has a fifty-two week low of $27.24 and a fifty-two week high of $95.91. The firm has a market capitalization of $1,470.00, a PE ratio of 46.51 and a beta of 1.04.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The firm had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same period in the previous year, the company earned ($0.09) EPS. Enanta Pharmaceuticals’s revenue was up 491.3% compared to the same quarter last year. research analysts anticipate that Enanta Pharmaceuticals will post 0.86 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Enanta Pharmaceuticals (ENTA) Receiving Somewhat Favorable Press Coverage, Report Shows” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/12/enanta-pharmaceuticals-enta-getting-somewhat-positive-media-coverage-report-shows.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.